Drug Trial Radar · NCT03303339
Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML)
Last checked: Nov 19, 2026Latest source record: Feb 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
72
Actual
Start
Nov 17, 2017
Primary completion
Nov 17, 2021
Study completion Nov 17, 2021
Sponsor
- Lead sponsor
- Cardiff OncologyIndustry
- Sponsor type
- Industry
- First posted
- Oct 6, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the phase 1b/2 study is to determine whether Onvansertib given orally daily for 5 consecutive days every 28 days is safe and tolerable in adult patients who have relapsed/refractory Acute Myeloid Leukemia (AML), or are ineligible for intensive induction therapy, and to determine the maximum tolerated dose and recommended phase 2 dose of Onvansertib in combination with decitabine or Onvansertib in combination with low-dose cytarabine. In the phase 2 portion of the study, Onvansertib in combination with decitabine will be studied to provide further data on the safety profile of the combination and to preliminarily assess the activity of the chosen combination in patients with untreated AML who are not candidates for aggressive induction therapy, or who have received one prior treatment for their AML.
Conditions
- Acute Myeloid Leukemia
Interventions
OnvansertibDrug
Onvansertib orally
CytarabineDrug
subcutaneously
DecitabineDrug
intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experienced Dose Limiting Toxicities (DLT)Time frame: Up to Day 28 of Cycle 1
- Number of Participants With Change From Baseline in Eastern Co-operative Oncology Group (ECOG) Performance StatusTime frame: Baseline and end of study (approximately up to up to 27 months)
- Phase 2: Number of Participants Who Achieved a Complete Response (CR)Time frame: Up to 27 months
- Number of Participants With Adverse Events (AEs)Time frame: Baseline up to 30 days after last dose of study drug (up to 27 months)
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
University of California Los Angeles
Los Angeles, California
Yale University
New Haven, Connecticut
University of Kansas Cancer Center
Westwood, Kansas
Allina Health Virginia Piper Cancer Institute
Minneapolis, Minnesota
Roswell Park Cancer Institute
Buffalo, New York
University of Texas Southwestern Medical Center
Dallas, Texas
MD Anderson Cancer Center
Houston, Texas
Virginia Cancer Specialists - Fairfax Office
Fairfax, Virginia
Seattle Cancer Care Alliance
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.